

The evaluation of serum brain-derived neurotrophic factor levels in pregnant women with hyperemesis gravidarum

Busra Demir Cendek¹, Betul Tokgoz Cakir¹, Rahime Bedir Fındık², Mujde Can Ibanoglu¹, Melahat Yildirim², Huseyin Tugrul Celik³, Ayse Filiz Yavuz²

¹Department of Gynecology, Ankara Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, Türkiye

²Department of Gynecology, T.C. Ministry of Health Ankara City Hospital, Ankara, Türkiye

³Department of Biochemistry, Yuzuncu Yil Private Hospital, Ankara, Türkiye

ABSTRACT

Objectives: The aim of this study was to investigate the relationship between levels of brain-derived neurotrophic factor (BDNF), which is considered a cause of conditions such as depression and eating disorders, and hyperemesis gravidarum (HG).

Material and methods: This study was conducted as a prospective study at Ankara Ataturk Training and Research Hospital in the Department of Obstetrics and Gynecology. The study included 73 pregnant women with singleton pregnancies (32 pregnant women with HG and 41 pregnant women without hyperemesis). Serum BDNF levels were compared between the two groups.

Results: The mean age of the study group was 27.3 ± 3.5 years and the body mass index (BMI) was 22.4 ± 2.7 kg/m². There is no statistically significant difference between the study group and the control group in terms of demographic data ($p > 0.05$). The pregnant women with HG were found to have significantly higher serum BDNF levels compared to the control group (349.1 ± 94.6 pg/mL vs 292.3 ± 86.01 , $p = 0.009$).

Conclusions: Serum BDNF levels that are low in psychiatric disorders such as depression or anxiety were found as high in pregnant women with HG.

Keywords: hyperemesis gravidarum; psychological factors; brain-derived neurotrophic factor; pregnancy

Ginekologia Polska 2023; 94, 11: 913–917

INTRODUCTION

Pregnancy is an important period in a woman's life, during which somatic, psychological and social changes take place. Hyperemesis gravidarum (HG) is defined as severe nausea and vomiting accompanied by weight loss, nutrient deficiency, and fluid-electrolyte imbalance during the first trimester of pregnancy. Nausea and vomiting are the most common somatic complaints experienced by approximately 75% of pregnant women during the first trimester [1], and these symptoms may continue to occur after the first trimester [1]. HG vomiting is a serious medical problem in pregnancy and remains an important cause of

fluid and electrolyte losses, acid-base imbalance, nutrient deficiencies, weight loss, dehydration, anemia, ketonuria, and frequent hospitalizations [1, 2]. HG not only affects pregnant women's physical health, but also their quality of life and affects their psychosocial condition [3]. Endocrine hormones such as human chorionic gonadotropin (HCG), estrogen, progesterone, and thyroid hormones, as well as psychosocial factors, may play an important role in the etiology and pathogenesis of HG [1]. However, the relative roles of psychological and biological factors in the development of this disorder remain controversial [2]. Depressive symptoms in pregnant women have been found to be

Corresponding author:

Mujde Can Ibanoglu

Department of Gynecology, Ankara Etlik Zubeyde Hanım Women's Health Training and Research Hospital, Ankara, Asagi Eglence, Emrah, Etlik Cd No:55, 06010 Keçioren/Ankara, Türkiye
e-mail: Drmujdec@gmail.com

Received: 15.12.2022 Accepted: 7.04.2023 Early publication date: 9.06.2023

This article is available in open access under Creative Commons Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

associated with severe nausea and vomiting during pregnancy [4]. A recent study has shown that there is an association between depression or anxiety scores and the severity of nausea and vomiting in early pregnancy [5]. Although there are a number of studies examining the association between psychiatric disorders and HG, none of these studies are sufficient to clarify the relationship to pathogenesis [6].

Brain-derived neurotrophic factor (BDNF) belongs to the nerve growth factor family, which is important for neuron survival and plasticity. It was originally described in the nervous system but has recently been shown to be present in ovarian tissue as well [7]. There is increasing evidence in the literature that BDNF expression in the limbic structure of the brain decreases with chronic stress, which may lead to an increase in mood disorders in patients with chronic stress [8, 9]. Another study has shown that chronic unpredictable stress leads to a decrease in the number of harvested oocytes, blastocyst development, and BDNF expression in antral follicles [10]. It has also been reported that increased oxidative stress and inflammation lead to a decrease in serum BDNF levels [11]. A study has shown that HG, which leads to inadequate food intake, suppresses the immune system and plays an important role in antioxidant levels [12].

In addition, there are numerous data suggesting that BDNF may play an important role in determining neuroplasticity in the hippocampus, regulating appetite and eating behavior, and learning and memory behavior [13]. In addition, serum BDNF levels have been found to be decreased in patients with anorexia nervosa [14] and increased in patients with fibromyalgia [15].

The purpose of this study is to discuss depression, anxiety, eating disorders, etc. The aim of this study is to investigate BDNF serum level in pregnant women with hyperemesis gravidarum.

MATERIAL AND METHODS

This study followed the Helsinki Declaration on human subject research and was approved by the Ethics Committee of Ankara Yildirim Beyazit University (Date: 25.03.2013, Approval No: 37).

This study is conducted as a prospective study at Ankara Atatürk Training and Research Hospital in the Department of Obstetrics and Gynecology between February 2013 and July 2013. All participants provided written informed consent. Seventy-three pregnant women participated in the study [32 pregnant women with HG and 41 pregnant women without hyperemesis (control group)]. All participants were selected from pregnant women presenting to our obstetric outpatient clinic during the first trimester of their pregnancy. HG was defined as persistent nausea and the occurrence of three or more episodes of vomiting per day, positive ketonuria (at least 1+) on urine puncture test without identifiable

causes, or 5% weight loss during the current pregnancy. Exclusion criteria for all participants were any type of liver, kidney, or thyroid disease, gastritis, pre-existing systemic or infectious diseases, trophoblastic gestational diseases, gastrointestinal disorders, metabolic disorders, collagen vascular disease, inflammatory diseases, fibromyalgia, chronic hypertension, neuropsychiatric disorders, history of diabetes mellitus or gestational diabetes, smoking habits, alcohol consumption, urinary tract infections, and multiple pregnancies. All pregnant women in the study had a history of regular menstrual cycles before conception and no polycystic ovaries, which can alter BDNF serum levels. All participants refused to take antipsychotics or antidepressants. Patients' characteristic features [age, gravidity, parity, body mass index (BMI), etc.] were recorded. Gestational age was determined for both the study and control groups based on the date of last menstruation and first trimester ultrasound findings. BMI was calculated as weight (in kg) divided by height (in metres) squared. While the patients were sitting upright, blood samples were collected from the antecubital vein between 08:00 and 10:00 after a 12-hour fasting period. Blood samples of 10cc were collected with a tube containing aprotinin and ethylenediaminetetraacetic acid (EDTA)-2Na and immediately centrifuged at 3500 g for 15 minutes at 4°C and stored at -80°C until processing and thawed immediately before analysis.

Determination of brain-derived neurotrophic factor

Maternal plasma concentration of BDNF were determined using sensitive and specific immunoassays (ELISA kit, Boster Immunoleader, catalogue number EK0307). The immunoassay was performed in duplicate and utilized a sandwich enzyme-based technique and had been validated for plasma determinations of the analytes. Serum concentration values were expressed pg/mL.

Statistical analysis

Statistical analysis was performed with the software IBM SPSS 25 (Statistical Package for Social Sciences) (New York, NY, USA). The Shapiro-Wilk test was used to check whether the data conformed to the normal distribution. Continuous variables were expressed as mean and standard deviation or median and minimum-maximum/interquartile range (IQR) for normally and nonnormally distributed data, respectively; categorical variables were expressed in numbers and percentages. For normally distributed data, the independent-samples t test was used, and for non-normally distributed variables, the Mann Whitney U test was used. All statistical analyzes were performed with two weights, and a p value of < 0.05 was considered statistically significant.

Table 1. Demographic data of hyperemesis gravidarum (HG) and control groups

	Control group (n = 41)	HG group (n = 32)	p value
Age (years)	27.3 ± 3.5	26.6 ± 5.5	0.516
Gravida (n)	2.03 ± 1.3	2.17 ± 1.3	0.557
Parity (n)	0.84 ± 1.1	0.76 ± 0.9	0.928
Gestational age (week)	9.2 ± 1.3	9.4 ± 1.3	0.398
Weight (kg)	59.1 ± 9.11	62.5 ± 9.01	0.111
Body mass index (kg/m ²)	22.4 ± 2.7	23.8 ± 3.2	0.059

Table 2. Comparison of the biochemical parameters and BDNF levels of the groups

	Control group (n = 41)	HG group (n = 32)	p value
Hb (g/dL)	12.6 ± 1.4	12.4 ± 0.9	0.650
WBC (K/uL)	8.5 ± 1.7	9.2 ± 2.9	0.134
PLT (K/uL)	248.4 ± 77.1	268 ± 104.4	0.458
FBG (mg/dL)	84.97 ± 7.02	87.33 ± 11.67	0.310
SGOT (IU/L)	16.54 ± 3.91	18 ± 4.6	0.170
SGPT (IU/L)	12.15 ± 5.65	13.62 ± 6.40	0.730
Sodium (mmol/L)	138.2 ± 0.8	136.11 ± 2.39	0.070
Potassium (mmol/L)	4.1 ± 0.33	4.1 ± 0.59	0.840
Urea (mg/dL)	16.69 ± 4.87	15.23 ± 4.51	0.220
Creatinine (mg/dL)	0.55 ± 0.11	0.51 ± 0.12	0.170
TSH (mU/mL)	1.46 ± 0.88	1.33 ± 1.14	0.090
BDNF (pg/mL)	292.3 ± 86.01	349.1 ± 94.6	0.009

Data were expressed as mean ± SD and Student t-test was used for statistical analyses

BDNF — brain-derived neurotrophic factor; FBG — fasting blood glucose; Hb — hemoglobin; HG — hyperemesis gravidarum; PLT — platelets; SGOT — serum glutamic oxaloacetic transaminase; SGPT — serum glutamic-pyruvic transaminase; TSH — thyroid stimulating hormone; WBC — white blood cell count

RESULTS

A total of 73 pregnant women (32 women with HG and 41 women without HG) were included in the study. There were no statistically significant differences between patients' age, week of gestation, body mass index (Tab. 1), serum levels of hemoglobin, white blood cell count, platelet count, fasting blood glucose levels, the serum levels of glutamate oxaloacetic transaminase, the serum levels of glutamate pyruvic transaminase, the serum sodium and potassium levels, urea, creatinine, and the serum levels of thyroid-stimulating hormone between HG and the control groups of the study (Tab. 2) ($p > 0.05$). Table 1 shows the demographic characteristics of the two groups HG and the control group. Serum BDNF levels were higher in the HG group than in the study control group (349.1 ± 94.6 pg/mL vs 292.3 ± 86.01 p = 0.009). No correlations were found between BDNF levels, maternal age, BMI, and serum biochemical parameters in the study ($p > 0.05$).

DISCUSSION

In the current study, we found that serum BDNF levels were higher in pregnant women with HG compared with control subjects. BDNF is expressed in many parts of the human brain [16] and plays an important role in various brain functions, such as synapse development, plasticity, neuronal connections, immature neurons, and survival of mature neurons [17]. Based on previous studies, circulating BDNF levels are thought to directly reflect BDNF levels in the brain [18]. Significantly lower serum BDNF levels have been found in neurodegenerative diseases such as Parkinson's disease than in control groups [19]. Inflammation and increased oxidative stress can also lower BDNF levels in patients' blood [11, 12]. In addition, it is well documented that BDNF plays an important role in the proper functioning of the brain and nervous system [17, 20]. A number of studies have shown that BDNF is an important component of the nervous system and acts as a messenger between

cells in response to stress [8, 21, 22]. Recent studies have shown that BDNF is associated not only with stress-related mood disorders [9] but also with reproductive disorders such as polycystic ovary syndrome [23] and infertility [24], with infertile women being more prone to depression and anxiety [25, 26]. Serum BDNF levels have been shown to increase in patients taking antidepressants and during remission of depression [27, 28]. Several studies have shown that pregnant women with HG are vulnerable to depression and anxiety [29, 30]. The severity of nausea and vomiting has been found to correlate with the level of anxiety and depression [30]. Simsek et al. [31] studied depression and anxiety scores in pregnant women with HG and found that patients with HG had significantly higher depression and anxiety scores than controls. However, this conclusion has not been confirmed in other studies [32]. Although BDNF levels decrease during depression, we found in this study that pregnant women with HG had higher serum BDNF levels. This finding suggests that psychological factors may not be as influential in the etiology of HG as previously thought. Advanced HG may lead to chronic diseases such as Wernicke encephalopathy [33]. We hypothesize that high BDNF levels on HG may have a protective effect on the brain against the development of central nervous system disorders such as Wernicke encephalopathy, which is associated with severe HG. Another explanation for the high BDNF levels could be the compensatory process of eating habits or loss of appetite during the first trimester in pregnant women with HG. There is ample evidence that BDNF plays an important role in weight control and eating behavior as well as neuroplasticity and memory behavior in the hippocampus [13]. Patients with anorexia nervosa (AN) and those with short-term weight gain were found to have significantly increased serum BDNF concentrations during the remission phase compared with acutely underweight patients AN [14]. Because there were no statistically significant differences in weight and BMI between HG and control groups in the present study, we cannot say with certainty that the increased BDNF levels are related to weight loss, but we hypothesize that the changes in serum BDNF levels may be related to appetite and eating behavior in patients with HG. In addition, BDNF levels may have increased in a compensatory manner to stimulate appetite in pregnant women with HG. However, further studies are needed to support this hypothesis.

Finally, there are some limitations in our study. BDNF levels may change during pregnancy, which may be related to the changes in pregnancy. To compare the status of different gestational weeks, the use of percentiles will lead to more objective conclusions. A larger number of studied populations is necessary not only to draw more concrete conclusions, but also to determine percentile ranks for weeks of gestation and different stages HG.

CONCLUSIONS

In conclusion, BDNF serum levels were higher in pregnant women with HG. This finding might be related to the defense mechanisms of the brain to cope with HG and its complications such as hunger, anorexia, Wernicke encephalopathy, etc. in the early stages and protect the pregnant women from the worsening effects of the disease. As far as we know, the present study is the first on this topic and suggests that psychological factors do not play a major role in the etiology of hyperemesis. However, further controlled studies are needed to support our findings.

Article information and declarations

Conflict of interests

All authors declare no conflict of interest.

REFERENCES

- Ismail SK, Kenny L. Review on hyperemesis gravidarum. *Best Pract Res Clin Gastroenterol.* 2007; 21(5): 755–769, doi: [10.1016/j.bpg.2007.05.008](https://doi.org/10.1016/j.bpg.2007.05.008), indexed in Pubmed: [17889806](https://pubmed.ncbi.nlm.nih.gov/17889806/).
- Verberg MFG, Gillott DJ, Al-Fardan N, et al. Hyperemesis gravidarum, a literature review. *Hum Reprod Update.* 2005; 11(5): 527–539, doi: [10.1093/humupd/dmi021](https://doi.org/10.1093/humupd/dmi021), indexed in Pubmed: [16006438](https://pubmed.ncbi.nlm.nih.gov/16006438/).
- Munch S, Korst LM, Hernandez GD, et al. Health-related quality of life in women with nausea and vomiting of pregnancy: the importance of psychosocial context. *J Perinatol.* 2011; 31(1): 10–20, doi: [10.1038/jp.2010.54](https://doi.org/10.1038/jp.2010.54), indexed in Pubmed: [20410906](https://pubmed.ncbi.nlm.nih.gov/20410906/).
- Mazzotta P, Stewart D, Atanackovic G, et al. Psychosocial morbidity among women with nausea and vomiting of pregnancy: prevalence and association with anti-emetic therapy. *J Psychosom Obstet Gynaecol.* 2000; 21(3): 129–136, doi: [10.3109/01674820009075620](https://doi.org/10.3109/01674820009075620), indexed in Pubmed: [11076334](https://pubmed.ncbi.nlm.nih.gov/11076334/).
- Köken G, Yilmazer M, Cosar E, et al. Nausea and vomiting in early pregnancy: relationship with anxiety and depression. *J Psychosom Obstet Gynaecol.* 2008; 29(2): 91–95, doi: [10.1080/01674820701733697](https://doi.org/10.1080/01674820701733697), indexed in Pubmed: [18655256](https://pubmed.ncbi.nlm.nih.gov/18655256/).
- Kim DR, Connolly KR, Cristancho P, et al. Psychiatric consultation of patients with hyperemesis gravidarum. *Arch Womens Ment Health.* 2009; 12(2): 61–67, doi: [10.1007/s00737-009-0064-7](https://doi.org/10.1007/s00737-009-0064-7), indexed in Pubmed: [19263196](https://pubmed.ncbi.nlm.nih.gov/19263196/).
- Seifer DB, Feng Bo, Shelden RM, et al. Brain-derived neurotrophic factor: a novel human ovarian follicular protein. *J Clin Endocrinol Metab.* 2002; 87(2): 655–659, doi: [10.1210/jcem.87.2.8213](https://doi.org/10.1210/jcem.87.2.8213), indexed in Pubmed: [11836300](https://pubmed.ncbi.nlm.nih.gov/11836300/).
- Larsen MH, Mikkelsen JD, Hay-Schmidt A, et al. Regulation of brain-derived neurotrophic factor (BDNF) in the chronic unpredictable stress rat model and the effects of chronic antidepressant treatment. *J Psychiatr Res.* 2010; 44(13): 808–816, doi: [10.1016/j.jpsychires.2010.01.005](https://doi.org/10.1016/j.jpsychires.2010.01.005), indexed in Pubmed: [20172535](https://pubmed.ncbi.nlm.nih.gov/20172535/).
- Martinowich K, Manji H, Lu B. New insights into BDNF function in depression and anxiety. *Nat Neurosci.* 2007; 10(9): 1089–1093, doi: [10.1038/nn1971](https://doi.org/10.1038/nn1971), indexed in Pubmed: [17726474](https://pubmed.ncbi.nlm.nih.gov/17726474/).
- Wu LM, Hu MH, Tong XH, et al. Chronic unpredictable stress decreases expression of brain-derived neurotrophic factor (BDNF) in mouse ovaries: relationship to oocytes developmental potential. *PLoS One.* 2012; 7(12): e52331, doi: [10.1371/journal.pone.0052331](https://doi.org/10.1371/journal.pone.0052331), indexed in Pubmed: [23284991](https://pubmed.ncbi.nlm.nih.gov/23284991/).
- Zhao HF, Li Q, Li Y. Long-term ginsenoside administration prevents memory loss in aged female C57BL/6J mice by modulating the redox status and up-regulating the plasticity-related proteins in hippocampus. *Neuroscience.* 2011; 183: 189–202, doi: [10.1016/j.neuroscience.2011.03.048](https://doi.org/10.1016/j.neuroscience.2011.03.048), indexed in Pubmed: [21463662](https://pubmed.ncbi.nlm.nih.gov/21463662/).
- Ege S, Bademkiran MH, Peker N, et al. Evaluation of catalase, myeloperoxidase and ferroxidase values in pregnant women with hyperemesis gravidarum. *Ginekol Pol.* 2019; 90(11): 651–655, doi: [10.5603/GP.2019.0110](https://doi.org/10.5603/GP.2019.0110), indexed in Pubmed: [31802466](https://pubmed.ncbi.nlm.nih.gov/31802466/).

13. Dmitrzak-Weglarz M, Skibinska M, Slopian A, et al. Serum neurotrophin concentrations in polish adolescent girls with anorexia nervosa. *Neuropsychobiology*. 2013; 67(1): 25–32, doi: [10.1159/000343500](https://doi.org/10.1159/000343500), indexed in Pubmed: [23221923](https://pubmed.ncbi.nlm.nih.gov/23221923/).
14. Zwipp J, Hass J, Schober I, et al. Serum brain-derived neurotrophic factor and cognitive functioning in underweight, weight-recovered and partially weight-recovered females with anorexia nervosa. *Prog Neuropsychopharmacol Biol Psychiatry*. 2014; 54: 163–169, doi: [10.1016/j.pnpbp.2014.05.006](https://doi.org/10.1016/j.pnpbp.2014.05.006), indexed in Pubmed: [24859292](https://pubmed.ncbi.nlm.nih.gov/24859292/).
15. Laske C, Banschbach S, Stransky E, et al. Increased BDNF serum concentration in fibromyalgia with or without depression or antidepressants. *J Psychiatr Res*. 2007; 41(7): 600–605, doi: [10.1016/j.jpsy-chires.2006.02.007](https://doi.org/10.1016/j.jpsy-chires.2006.02.007), indexed in Pubmed: [16600301](https://pubmed.ncbi.nlm.nih.gov/16600301/).
16. Murer MG, Boissiere F, Yan Q, et al. An immunohistochemical study of the distribution of brain-derived neurotrophic factor in the adult human brain, with particular reference to Alzheimer's disease. *Neuroscience*. 1999; 88(4): 1015–1032, doi: [10.1016/s0306-4522\(98\)00219-x](https://doi.org/10.1016/s0306-4522(98)00219-x), indexed in Pubmed: [10336117](https://pubmed.ncbi.nlm.nih.gov/10336117/).
17. Lu B, Nagappan G, Guan X, et al. BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. *Nat Rev Neurosci*. 2013; 14(6): 401–416, doi: [10.1038/nrn3505](https://doi.org/10.1038/nrn3505), indexed in Pubmed: [23674053](https://pubmed.ncbi.nlm.nih.gov/23674053/).
18. Blugeot A, Rivat C, Bouvier E, et al. Vulnerability to depression: from brain neuroplasticity to identification of biomarkers. *J Neurosci*. 2011; 31(36): 12889–12899, doi: [10.1523/JNEUROSCI.1309-11.2011](https://doi.org/10.1523/JNEUROSCI.1309-11.2011), indexed in Pubmed: [21900567](https://pubmed.ncbi.nlm.nih.gov/21900567/).
19. Scalzo P, Kümmer A, Bretas TL, et al. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease. *J Neurol*. 2010; 257(4): 540–545, doi: [10.1007/s00415-009-5357-2](https://doi.org/10.1007/s00415-009-5357-2), indexed in Pubmed: [19847468](https://pubmed.ncbi.nlm.nih.gov/19847468/).
20. Monteggia LM, Barrot M, Powell CM, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. *Proc Natl Acad Sci USA*. 2004; 101(29): 10827–10832, doi: [10.1073/pnas.0402141101](https://doi.org/10.1073/pnas.0402141101), indexed in Pubmed: [15249684](https://pubmed.ncbi.nlm.nih.gov/15249684/).
21. Berton O, McClung CA, Dileone RJ, et al. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. *Science*. 2006; 311(5762): 864–868, doi: [10.1126/science.1120972](https://doi.org/10.1126/science.1120972), indexed in Pubmed: [16469931](https://pubmed.ncbi.nlm.nih.gov/16469931/).
22. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. *Biol Psychiatry*. 2006; 59(12): 1116–1127, doi: [10.1016/j.biopsych.2006.02.013](https://doi.org/10.1016/j.biopsych.2006.02.013), indexed in Pubmed: [16631126](https://pubmed.ncbi.nlm.nih.gov/16631126/).
23. Russo N, Russo M, Daino D, et al. Polycystic ovary syndrome: brain-derived neurotrophic factor (BDNF) plasma and follicular fluid levels. *Gynecol Endocrinol*. 2012; 28(4): 241–244, doi: [10.3109/09513590.2011.613969](https://doi.org/10.3109/09513590.2011.613969), indexed in Pubmed: [22420627](https://pubmed.ncbi.nlm.nih.gov/22420627/).
24. Sadeu JC, Doedée AM, Neal MS, et al. Neurotrophins (BDNF and NGF) in follicular fluid of women with different infertility diagnoses. *Reprod Biomed Online*. 2012; 24(2): 174–179, doi: [10.1016/j.rbmo.2011.11.011](https://doi.org/10.1016/j.rbmo.2011.11.011), indexed in Pubmed: [22197602](https://pubmed.ncbi.nlm.nih.gov/22197602/).
25. Boivin J, Takefman JE. Impact of the in-vitro fertilization process on emotional, physical and relational variables. *Hum Reprod*. 1996; 11(4): 903–907, doi: [10.1093/oxfordjournals.humrep.a019276](https://doi.org/10.1093/oxfordjournals.humrep.a019276), indexed in Pubmed: [8671350](https://pubmed.ncbi.nlm.nih.gov/8671350/).
26. Cousineau TM, Domar AD. Psychological impact of infertility. *Best Pract Res Clin Obstet Gynaecol*. 2007; 21(2): 293–308, doi: [10.1016/j.bpobgyn.2006.12.003](https://doi.org/10.1016/j.bpobgyn.2006.12.003), indexed in Pubmed: [17241818](https://pubmed.ncbi.nlm.nih.gov/17241818/).
27. Kotan Z, Sarandöl A, Saygin Ek, et al. Depression, neuroplasticity and neurotrophic factors. *Current Approaches in Psychiatry*. 2009; 1(1): 22–35.
28. van der Meij A, Comijs HC, Dols A, et al. BDNF in late-life depression: effect of SSRI usage and interaction with childhood abuse. *Psychoneuroendocrinology*. 2014; 43: 81–89, doi: [10.1016/j.psyneuen.2014.02.001](https://doi.org/10.1016/j.psyneuen.2014.02.001), indexed in Pubmed: [24703173](https://pubmed.ncbi.nlm.nih.gov/24703173/).
29. Tan PC, Zaidi SN, Azmi N, et al. Depression, anxiety, stress and hyperemesis gravidarum: temporal and case controlled correlates. *PLoS One*. 2014; 9(3): e92036, doi: [10.1371/journal.pone.0092036](https://doi.org/10.1371/journal.pone.0092036), indexed in Pubmed: [24637791](https://pubmed.ncbi.nlm.nih.gov/24637791/).
30. Swallow BL, Lindow SW, Masson EA, et al. Psychological health in early pregnancy: relationship with nausea and vomiting. *J Obstet Gynaecol*. 2004; 24(1): 28–32, doi: [10.1080/01443610310001620251](https://doi.org/10.1080/01443610310001620251), indexed in Pubmed: [14675977](https://pubmed.ncbi.nlm.nih.gov/14675977/).
31. Simşek Y, Celik O, Yilmaz E, et al. Assessment of anxiety and depression levels of pregnant women with hyperemesis gravidarum in a case-control study. *J Turk Ger Gynecol Assoc*. 2012; 13(1): 32–36, doi: [10.5152/jtgga.2012.01](https://doi.org/10.5152/jtgga.2012.01), indexed in Pubmed: [24627672](https://pubmed.ncbi.nlm.nih.gov/24627672/).
32. Tsang IS, Katz VL, Wells SD. Maternal and fetal outcomes in hyperemesis gravidarum. *Int J Gynaecol Obstet*. 1996; 55(3): 231–235, doi: [10.1016/s0020-7292\(96\)02778-6](https://doi.org/10.1016/s0020-7292(96)02778-6), indexed in Pubmed: [9003948](https://pubmed.ncbi.nlm.nih.gov/9003948/).
33. Yoon CK, Chang MH, Lee DC. Wernicke-Korsakoff syndrome associated with hyperemesis gravidarum. *Korean J Ophthalmol*. 2005; 19(3): 239–242, doi: [10.3341/kjo.2005.19.3.239](https://doi.org/10.3341/kjo.2005.19.3.239), indexed in Pubmed: [16209289](https://pubmed.ncbi.nlm.nih.gov/16209289/).